BioCryst Pharmaceuticals
BCRX
$8.09
Share price
-2.06%
Change (1 day)
7.58%
Change (1 year)
Categories
Earnings for BioCryst Pharmaceuticals (BCRX)
Earnings in 2025 (TTM): -$51.19 Million USD
According to BioCryst Pharmaceuticals 's latest financial reports the company's current earnings are $0.50 Billion USD. In 2024 the company made an earning of -$86.96 Million USD, an increase over its 2023 earnings that were of -$0.23 Billion USD. The earnings displayed on this page is the company's Pretax Income.
Earnings history for BioCryst Pharmaceuticals from 1996 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -$51.19 Million | -41.14% |
| 2024 | -$86.96 Million | -61.56% |
| 2023 | -$0.23 Billion | -7.43% |
| 2022 | -$0.25 Billion | 34.42% |
| 2021 | -$0.19 Billion | -0.55% |
| 2020 | -$0.19 Billion | 67.88% |
| 2019 | -$0.11 Billion | 7.55% |
| 2018 | -$0.11 Billion | 53.92% |
| 2017 | -$65.79 Million | 19.29% |
| 2016 | -$55.15 Million | 28.19% |
| 2015 | -$43.02 Million | -4.8% |
| 2014 | -$45.19 Million | 50.09% |
| 2013 | -$30.11 Million | -23.29% |
| 2012 | -$39.25 Million | -26.19% |
| 2011 | -$53.18 Million | 54.78% |
| 2010 | -$34.36 Million | 150.1% |
| 2009 | -$13.74 Million | -49.43% |
| 2008 | -$27.17 Million | 14.07% |
| 2007 | -$23.82 Million | -49.31% |
| 2006 | -$46.98 Million | 72.87% |
| 2005 | -$27.18 Million | 22.08% |
| 2004 | -$22.27 Million | 75.3% |
| 2003 | -$12.7 Million | -25.36% |
| 2002 | -$17.02 Million | 225.05% |
| 2001 | -$5.24 Million | -56.6% |
| 2000 | -$12.07 Million | 50.63% |
| 1999 | -$8.01 Million | 38.05% |
| 1998 | -$5.8 Million | -52.46% |
| 1997 | -$12.2 Million | 58.44% |
| 1996 | -$7.7 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | -$1.84 Million | -96.41% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -$0.17 Billion | 220.80% | 🇺🇸 USA |
 NanoViricides NNVC | -$9.73 Million | -81.00% | 🇺🇸 USA |
 Novavax NVAX | $0.51 B | -1,096.85% | 🇺🇸 USA |
 Gilead Sciences GILD | $6.82 B | -13,434.77% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -$0.22 Billion | 324.39% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $5.40 B | -10,663.91% | 🇬🇧 UK |
 Emergent BioSolutions
EBS | -$0.9 Million | -98.24% | 🇺🇸 USA |
 Cel-Sci
CVM | -$25.9 Million | -49.40% | 🇺🇸 USA |